Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis

BACKGROUND: Fatigue is one of the most common adverse effects associated with cancer immunotherapy using checkpoint inhibitors (CPIs). Because treatment-related fatigue also frequently occurs in patients treated with non-immunological therapies, our study aimed to compare the incidence of fatigue in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiss, I., Kuhn, M., Hrusak, K., Buchler, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271472/
https://www.ncbi.nlm.nih.gov/pubmed/35576697
http://dx.doi.org/10.1016/j.esmoop.2022.100474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271472/
https://www.ncbi.nlm.nih.gov/pubmed/35576697
http://dx.doi.org/10.1016/j.esmoop.2022.100474

Ejemplares similares